Search

Ghalib A Alkhatib

from Birmingham, AL
Age ~68
Get Report
Also known as:
Ghalib Alkhatib, Alkhatib Ghalib, Abbas Alkhatib, Ghalib Alkahtib
Related to:
Kurt A ApostolAllan Apostol, 53Alaine Apostol, 25Ayah G Alkhatib, 29
Connected to:
Burhan Y Alkhatib, 66Noor M AlkhatibMike Alkin, 72Hiba Z Alkinani, 45Carin L Alkire, 57Donovan E Alkire, 34Phil D Alkire, 54Ali R Alkitbi, 33Priscilla L Alkowatli, 45Marwa Alkurdi, 38

Ghalib Alkhatib Phones & Addresses

  • Birmingham, AL
  • 7049 Westwind Dr, El Paso, TX 79912
  • 13264 Penneagle Dr, Carmel, IN 46033
  • 3 Pooks Hill Rd, Bethesda, MD 20814
  • Indianapolis, IN
  • Leeds, AL
  • Silver Spring, MD
  • 7049 Westwind Dr APT 4012, El Paso, TX 79912

Resumes

Resumes

Ghalib Alkhatib Photo 1

Senior Research Fellow

View page
Location:
Birmingham, AL
Industry:
Research
Work:
Southern Research Institute
Senior Research Fellow
Ghalib Alkhatib Photo 2

Senior Scientist And Lab Director

View page
Work:
Trialtus Bioscience
Senior Scientist and Lab Director
Ghalib Alkhatib Photo 3

Ghalib Alkhatib

View page
Ghalib Alkhatib Photo 4

Ghalib Alkhatib Birmingham, AL

View page
Work:
Southern Research Institute

Jul 2012 to 2000
Senior Research Fellow
Dept. of Biomedical Sciences
Tech, Texas, US
Feb 2010 to Jun 2012
Professor
Indiana University School of Medicine
Indianapolis, IN
Jul 2003 to Dec 2009
Associate Professor
Indiana University School of Medicine
Indianapolis, IN
Dec 1997 to Jul 2003
Assistant Professor
Department of Medical Genetics
Vancouver, BC
Nov 1993 to Feb 1995
Faculty Research Associate
Education:
Mount Sinai Hospital Research Institute
Toronto, ON
Sep 1990 to Nov 1993
Immunology & Neurobiology
Biotechnology Research Institute
Montral, QC
Sep 1988 to Sep 1990
Ph.D. in Genetics Group
McGill University
Montral, QC
1988 to 1989
Ph.D. in Molecular Virology
Pahlavi University
1979 to 1980
B.Sc. in Biology
Ghalib Alkhatib Photo 5

Ghalib Alkhatib Birmingham, AL

View page
Work:
Southern Research Institute

Jul 2012 to 2000
Senior Research Fellow
Dept. of Biomedical Sciences
Tech, Texas, US
Feb 2010 to Jun 2012
Professor
Indiana University School of Medicine
Indianapolis, IN
Jul 2003 to Dec 2009
Associate Professor
Indiana University School of Medicine
Indianapolis, IN
Dec 1997 to Jul 2003
Assistant Professor
Department of Medical Genetics
Vancouver, BC
Nov 1993 to Feb 1995
Faculty Research Associate
Education:
Mount Sinai Hospital Research Institute
Toronto, ON
Sep 1990 to Nov 1993
Immunology & Neurobiology
Biotechnology Research Institute
Montral, QC
Sep 1988 to Sep 1990
Ph.D. in Genetics Group
McGill University
Montral, QC
1988 to 1989
Ph.D. in Molecular Virology
Pahlavi University
1979 to 1980
B.Sc. in Biology

Publications

Us Patents

Cc Chemokine Receptor 5 Dna, New Animal Models And Therapeutic Agents For Hiv Infection

View page
US Patent:
20030195348, Oct 16, 2003
Filed:
May 15, 2003
Appl. No.:
10/439845
Inventors:
Christophe Combadiere - Rockville MD, US
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Bethesda MD, US
Edward Berger - Rockville MD, US
Philip Murphy - Rockville MD, US
Christopher Broder - Rockville MD, US
Paul Kennedy - Silver Spring MD, US
International Classification:
C07H021/04
C07K014/715
C12P021/02
C12N005/06
A61K038/16
US Classification:
536/023500, 530/350000, 514/012000, 435/069100, 435/320100, 435/325000
Abstract:
The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

Strl33, A Human Fusion Accessory Factor Associated With Hiv Infection

View page
US Patent:
20030203450, Oct 30, 2003
Filed:
Jun 9, 2003
Appl. No.:
10/458110
Inventors:
Joshua Farber - Washington DC, US
Fang Liao - Taipei, TW
Ghalib Alkhatib - Carmel IN, US
Edward Berger - Rockville MD, US
International Classification:
A01K067/027
C07H021/04
C12P021/02
C12N005/06
C07K014/705
C12N005/06
US Classification:
435/069100, 435/320100, 435/354000, 530/350000, 536/023500, 800/010000, 800/014000, 800/018000
Abstract:
The susceptibility to human immunodeficiency virus (HIV) infection depends on the cell surface expression of the human CD4 molecule and a human fusion accessory factor associated with HIV infection (STRL33). STRL33 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. STRL33 plays a role in the membrane fusion step of HIV infection for both TCL-tropic and M-tropic variants of HIV. The invention provides STRL33 polypeptide and polynucleotide sequences encoding STRL33 polypeptide. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and STRL33 provides valuable tools for the continuing research of HIV infection and the development of more effective anti-HIV therapeutics. In addition, antibodies against STRL33, isolated and purified peptide fragments of STRL33, and STRL33-binding biologic agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics.

Cc Chemokine Receptor 5 Dna, New Animal Models And Therapeutic Agents For Hiv Infection

View page
US Patent:
20040259785, Dec 23, 2004
Filed:
Oct 31, 2003
Appl. No.:
10/700313
Inventors:
Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward Berger - Rockville MD, US
Philip Murphy - Rockville MD, US
Christopher Broder - Rockville MD, US
Paul Kennedy - Silver Spring MD, US
Assignee:
The Govt. of the USA, as represented by the Secretary of the Dept. of Health & Human Services
International Classification:
G01N033/00
C12Q001/68
A61K038/17
C07K014/715
US Classification:
514/012000, 435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 536/023200, 800/003000
Abstract:
The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

Cc Chemokine Receptor 5 Dna, New Animal Models And Therapeutic Agents For Hiv Infection

View page
US Patent:
20070087990, Apr 19, 2007
Filed:
Nov 7, 2006
Appl. No.:
11/594375
Inventors:
Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward Berger - Rockville MD, US
Philip Murphy - Rockville MD, US
Christopher Broder - Rockville MD, US
Paul Kennedy - Silver Spring MD, US
International Classification:
A61K 31/70
C12P 21/06
A01N 43/04
US Classification:
514044000, 435069100
Abstract:
The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.

Cc Chemokine Receptor 5 Dna, New Animal Models And Therapeutic Agents For Hiv Infection

View page
US Patent:
20080241167, Oct 2, 2008
Filed:
Mar 7, 2008
Appl. No.:
12/044845
Inventors:
Christophe Combadiere - Paris, FR
Yu Feng - San Diego CA, US
Ghalib Alkhatib - Carmel IN, US
Edward A. Berger - Rockville MD, US
Philip M. Murphy - Rockville MD, US
Christopher C. Broder - Rockville MD, US
Paul E. Kennedy - Silver Spring MD, US
International Classification:
A61K 39/395
C12N 5/06
G01N 33/566
G01N 33/53
C12Q 1/70
C12Q 1/02
A61K 31/7052
C12N 15/87
A61P 31/18
US Classification:
4241721, 435375, 436501, 435 72, 435 5, 435 29, 514 44, 435440
Abstract:
The susceptibility of human macrophages to human immunodeficiency virus (HIV) infection depends on cell surface expression of the human CD4 molecule and CC cytokine receptor 5. CCR5 is a member of the 7-transmembrane segment superfamily of G-protein-coupled cell surface molecules. CCR5 plays an essential role in the membrane fusion step of infection by some HIV isolates. The establishment of stable, nonhuman cell lines and transgenic mammals having cells that coexpress human CD4 and CCR5 provides valuable tools for the continuing research of HIV infection. In addition, antibodies which bind to CCR5, CCR5 variants, and CCR5-binding agents, capable of blocking membrane fusion between HIV and target cells represent potential anti-HIV therapeutics for macrophage-tropic strains of HIV.
Control profile
Ghalib A Alkhatib from Birmingham, AL, age ~68 Get Report